-
Clinical Trials & Development5 days agoNovo Nordisk’s Wegovy helps free 40% of kids from obesity in phase 3 trial
Novo Nordisk has reported a phase 3 weight-management win for Wegovy in children, with two out of five kids no longer classified as having obesity after...
-
Clinical Trials & Development5 days agoSTAT+: Roivant lung disease drug hits mid-stage study goals
These positive results could open up a new way to treat serious lung disease.
-
Clinical Trials & Development5 days ago
Spyre’s 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
Spyre's three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a phase 2 win.
-
Clinical Trials & Development5 days agoSTAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company
A Novartis drug for a rare neuromuscular condition failed in a key study, the company's second major trial collapse in a matter of days.
-
Clinical Trials & Development5 days ago
Roche sweeps neurology corporate reputation rankings once again
Roche has retained its status as the neurology drugmaker that patient groups hold in the highest esteem, once again completing a clean sweep of PatientView’s corporate...
-
Clinical Trials & Development6 days ago
Novartis’ centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
The phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in...
-
Clinical Trials & Development6 days ago
Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability
Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival demonstrated by its OX40 agonist in a phase 2 study has proven the therapy’s...
-
Clinical Trials & Development6 days ago
Novo Nordisk STEP Young Phase 3 Data: 40.4% of Children Living with Obesity Achieved a BMI Below the Obesity Threshold with Semaglutide and Lifestyle Modification
Bagsværd, Denmark, 7 September 2026 – Novo Nordisk today announced first results from the STEP Young phase 3 trial, evaluating once-weekly semaglutide in combination with a...
-
Clinical Trials & Development6 days ago
When every treatment counts: How clinical trials are changing the outlook for non-Hodgkin lymphoma patients
Discover Andy Brown's long and arduous journey battling a type of non-Hodgkin lymphoma and how a clinical trial altered his treatment outlook. The post When every...
-
Clinical Trials & Development6 days agoNovartis hit as Lp(a) drug fails cardio outcomes trial
Novartis shares have slipped after it revealed its Lp(a)-targeted drug, pelacarsen, failed to reduce cardiovascular risks in a major phase 3 trial.
Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds
Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
